Moderna’s Covid Vaccine Gets Full FDA Approval For Use In Children 6 Months And Older
UNITED STATES, JUL 10 – The FDA’s full approval allows Moderna’s vaccine for children at increased risk, covering ages 6 months to 11 years, with 94.1% efficacy shown in adult trials, the company said.
- On Thursday, the FDA granted full approval for Moderna's Spikevax in children aged six months to 11 years at increased risk.
- The FDA granted full approval based on data from the KidCOVE trial, which showed that two 25 microgram doses of the vaccine are safe and elicit immune responses comparable to young adults.
- Following the FDA's full approval, Moderna's shares rose 2% to USD 33.45 in premarket trading, reflecting positive market reaction to the regulatory milestone.
- Moderna plans to have its updated Spikevax vaccine available for the 2025–26 respiratory season, with ongoing development of mRNA-1283 for high-risk adults, indicating preparations for future protection efforts.
Insights by Ground AI
Does this summary seem wrong?
61 Articles
61 Articles
Dr. McCullough on a Recent Revealing Study: Spike Protein Lingers — And Grows
In a stunning political and medical upheaval, 12 U.S. states have ignited a firestorm by pushing legislation to ban COVID-19 vaccines — declaring them unsafe, ineffective, and a symbol of misplaced trust. Health and Human Services Secretary Robert F.
Moderna’s ‘Toxic’ COVID Shot Gains FDA Approval For ‘Increased-Risk’ Kids
This post was published by Jon Fleetwood. Please visit his Substack and subscribe to support his work. Follow Jon: Instagram @realjonfleetwood / Twitter @JonMFleetwood / Facebook @realjonfleetwood Moderna, Inc. today announced that the U.S. Food and Drug Administration (FDA) “has approved the supplemental Biologics License Application (sBLA) for Spikevax®, the Company’s COVID-19 vaccine, in children 6 months through 11 years of age who are at in…
Coverage Details
Total News Sources61
Leaning Left4Leaning Right14Center26Last UpdatedBias Distribution59% Center
Bias Distribution
- 59% of the sources are Center
59% Center
C 59%
R 32%
Factuality
To view factuality data please Upgrade to Premium